🇺🇸 FDA
Pipeline program

GT-02287

GANX-001-V102

Phase 1 small_molecule active

Quick answer

GT-02287 for Parkinson Disease is a Phase 1 program (small_molecule) at Gain Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Gain Therapeutics
Indication
Parkinson Disease
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials